Most organs contain a variety differentiated cell types that are derived from a pool of uncommitted progenitor cells. How the correct number of different cell types are specified - the process of cell fate determination - is a central question in organogenesis. This problem applies to the pancreas, which contains exocrine cells, which produce digestive enzymes, and endocrine cells, which make pancreatic hormones, including insulin. The goal of this project is to understand the mechanism by which pancreatic progenitor cells are instructed to become exocrine or endocrine cells, through the process of cell fate determination. Previous work has suggested that Notch - a complex receptor signaling pathway that is widely used during embryogenesis to control differentiation - plays an important role determining pancreatic cell fate. This proposal aims to answer three questions. First, can manipulation of the Notch signal lead to changes in the proportion of exocrine and endocrine cells that form? This will be addressed by mis-expressing activators and inhibitors of the Notch pathway in transgenic mice to determine the effect on cell fate. Second, how are Notch signals regulated in the pancreas? This will be addressed by characterizing the expression of elements of the Notch pathway when known mediators of endocrine differentiation are expressed in chick embryos. Third, what is the function of the mouse Sel-1l protein, a negative regulator of Notch in C. elegans which is expressed in the mammalian pancreas. This will be addressed by inactivating the Sel-1l gene. Clarifying the mechanism by which cell fate decisions are made in the pancreas will enhance the general understanding of the process of organogenesis. Many degenerative diseases, including pancreatic insufficiency and type I diabetes, result from the loss important differentiated cell types. Practically, an understanding of the mechanisms by which the organism specifies such cell types may confer the ability to experimentally manipulate tissues for therapy.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Clinical Investigator Award (CIA) (K08)
Project #
1K08DK064136-01
Application #
6600976
Study Section
Diabetes, Endocrinology and Metabolic Diseases B Subcommittee (DDK)
Program Officer
Hyde, James F
Project Start
2003-07-01
Project End
2008-06-30
Budget Start
2003-07-01
Budget End
2004-06-30
Support Year
1
Fiscal Year
2003
Total Cost
$129,870
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Pasca di Magliano, Marina; Forsmark, Christopher; Freedman, Steven et al. (2013) Advances in acute and chronic pancreatitis: from development to inflammation and repair. Gastroenterology 144:e1-4
Stanger, Ben Z; Dor, Yuval (2006) Dissecting the cellular origins of pancreatic cancer. Cell Cycle 5:43-6
Hezel, Aram F; Kimmelman, Alec C; Stanger, Ben Z et al. (2006) Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 20:1218-49
Stanger, Ben Z; Datar, Radhika; Murtaugh, L Charles et al. (2005) Direct regulation of intestinal fate by Notch. Proc Natl Acad Sci U S A 102:12443-8
Stanger, Ben Z; Stiles, Bangyan; Lauwers, Gregory Y et al. (2005) Pten constrains centroacinar cell expansion and malignant transformation in the pancreas. Cancer Cell 8:185-95